Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 599.53 Million CNY | -21.62% |
| 2022 | 764.89 Million CNY | 32.11% |
| 2021 | 578.98 Million CNY | -0.77% |
| 2020 | 583.5 Million CNY | 4505.03% |
| 2019 | 12.67 Million CNY | -87.76% |
| 2018 | 103.55 Million CNY | -25.11% |
| 2017 | 138.27 Million CNY | 1079.97% |
| 2016 | 11.71 Million CNY | 118.7% |
| 2015 | 5.35 Million CNY | -34.14% |
| 2014 | 8.13 Million CNY | -52.93% |
| 2013 | 17.28 Million CNY | -70.96% |
| 2012 | 59.52 Million CNY | 15.57% |
| 2011 | 51.5 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 564.03 Million CNY | -7.9% |
| 2024 Q1 | 617.52 Million CNY | 3.0% |
| 2024 Q2 | 632 Million CNY | 2.34% |
| 2023 Q3 | 597.73 Million CNY | -0.82% |
| 2023 Q1 | 563.87 Million CNY | -26.28% |
| 2023 Q2 | 602.65 Million CNY | 6.88% |
| 2023 FY | 599.53 Million CNY | -21.62% |
| 2023 Q4 | 599.53 Million CNY | 0.3% |
| 2022 Q3 | 769.24 Million CNY | -1.09% |
| 2022 FY | 764.89 Million CNY | 32.11% |
| 2022 Q2 | 777.73 Million CNY | 0.07% |
| 2022 Q1 | 777.21 Million CNY | 34.24% |
| 2022 Q4 | 764.89 Million CNY | -0.57% |
| 2021 Q1 | 523.14 Million CNY | -10.34% |
| 2021 FY | 578.98 Million CNY | -0.77% |
| 2021 Q3 | 545.67 Million CNY | 2.79% |
| 2021 Q2 | 530.88 Million CNY | 1.48% |
| 2021 Q4 | 578.98 Million CNY | 6.1% |
| 2020 Q1 | 98.98 Million CNY | 681.22% |
| 2020 Q3 | 583.85 Million CNY | 518.9% |
| 2020 Q4 | 583.5 Million CNY | -0.06% |
| 2020 FY | 583.5 Million CNY | 4505.03% |
| 2020 Q2 | 94.33 Million CNY | -4.7% |
| 2019 Q1 | 96.33 Million CNY | -6.97% |
| 2019 FY | 12.67 Million CNY | -87.76% |
| 2019 Q4 | 12.67 Million CNY | -78.1% |
| 2019 Q2 | 28.6 Million CNY | -70.31% |
| 2019 Q3 | 57.86 Million CNY | 102.27% |
| 2018 Q4 | 103.55 Million CNY | 8.14% |
| 2018 Q2 | 110.15 Million CNY | 6.76% |
| 2018 Q1 | 103.18 Million CNY | -25.38% |
| 2018 FY | 103.55 Million CNY | -25.11% |
| 2018 Q3 | 95.75 Million CNY | -13.07% |
| 2017 Q1 | 134.37 Million CNY | 1046.71% |
| 2017 FY | 138.27 Million CNY | 1079.97% |
| 2017 Q4 | 138.27 Million CNY | -8.89% |
| 2017 Q3 | 151.76 Million CNY | 17.03% |
| 2017 Q2 | 129.67 Million CNY | -3.49% |
| 2016 FY | 11.71 Million CNY | 118.7% |
| 2016 Q3 | 6.05 Million CNY | -9.15% |
| 2016 Q2 | 6.66 Million CNY | 11.92% |
| 2016 Q1 | 5.95 Million CNY | 11.2% |
| 2016 Q4 | 11.71 Million CNY | 93.43% |
| 2015 Q2 | 12.05 Million CNY | 97.61% |
| 2015 FY | 5.35 Million CNY | -34.14% |
| 2015 Q3 | 6.88 Million CNY | -42.9% |
| 2015 Q4 | 5.35 Million CNY | -22.18% |
| 2015 Q1 | 6.1 Million CNY | -25.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 8.13 Million CNY | 0.0% |
| 2014 FY | 8.13 Million CNY | -52.93% |
| 2013 FY | 17.28 Million CNY | -70.96% |
| 2012 FY | 59.52 Million CNY | 15.57% |
| 2011 FY | 51.5 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 86.03% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.34 Billion CNY | 82.085% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | 16.044% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 47.206% |
| Medicalsystem Biotechnology Co., Ltd. | 108.17 Million CNY | -454.25% |
| Maccura Biotechnology Co.Ltd | 665.16 Million CNY | 9.866% |
| Guangdong Hybribio Biotech Co.,Ltd. | 56.65 Million CNY | -958.275% |
| BGI Genomics Co., Ltd. | 1.09 Billion CNY | 45.318% |
| Amoy Diagnostics Co., Ltd. | 108.34 Million CNY | -453.354% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | -60.038% |